Alterity Therapeutics (ATH) Q4 2026 TU earnings summary

Executive summary

• Achieved key regulatory milestone with FDA confirming a registrational pathway for ATH434 in Multiple System Atrophy (MSA), allowing a single pivotal Phase 3 trial plus confirmatory evidence for approval.

• Phase 3 trial activities for ATH434 are on track to initiate by year-end 2026, with design elements agreed upon with the FDA.

• Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximize long-term shareholder value.

• Strengthened governance with the appointment of an independent Non-Executive Director and completed a 1-for-50 share consolidation.

Financial highlights

• Cash and cash equivalents at 30 June 2026 totaled A$37.3 million.

• Operating cash outflows for the quarter were A$7.72 million.

• Received a A$3.98 million Australian R&D Tax Incentive refund after quarter-end.

• Net cash used in operating activities for the quarter was A$7.17 million; for the year, A$22.52 million.

• Net cash from financing activities for the year was A$19.13 million.

Outlook and guidance

• Pivotal Phase 3 trial for ATH434 in MSA expected to begin by year-end 2026.

• Estimated quarters of funding available is 5.2, based on current cash and operating outflows.

• Ongoing strategic and funding discussions with pharmaceutical companies to support late-stage development.